RxDoctor Payments DataLook up a doctor →

Matthew Hallman, MD

Pain Medicine · New Bern, NCNPI 1235586546

Payments from drug & device makers

$18,849in general payments, 2019–2025

Across 464 payments — averaging $40.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$7K
  • Medtronic$7K
  • Stimwave Technologies Incorporated$684
  • Abbott$530
  • Collegium Pharmaceutical, Inc.$448
  • AbbVie$374
  • plus $3K from 36 others

What the payments were for

  • Grants$5,00027%
  • Travel & lodging$3,23117%
  • Food & beverage$10,61856%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,849 in reported general payments places this provider in the 80th percentile of 182 pain medicine providers in North Carolina.

See all pain medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$211,132
Medicare patients
338
Services billed
4,702

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Buprenorphine93$24,727
Xtampza ErOxycodone Myristate41$24,205
BelbucaBuprenorphine Hcl32$22,248
UbrelvyUbrogepant11$11,430
Oxycodone Hcl301$5,851
Fentanyl44$5,635
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen276$5,605
SuboxoneBuprenorphine Hcl/Naloxone Hcl12$5,471
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen169$5,323
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl47$4,829
Gabapentin223$3,782
Pregabalin107$3,354
Lidocaine34$2,935
Morphine Sulfate ErMorphine Sulfate125$2,703
Methadone Hcl53$1,474

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca$448$46,45373 claims
AbbVieUbrelvy$374$11,43011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 182 pain medicine providers in North Carolina.

Other pain medicine in New Bern

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →